Ipsen to buy French biotech company ImCheck Therapeutics

Ipsen is set to purchase all issued and outstanding shares of the French biotechnology company ImCheck Therapeutics, which specialises in immuno-oncology therapies. Ipsen SAS’ fully owned subsidiary will pay ImCheck shareholders €350m ($406.6m) upon completion of the deal without any adjustments for cash or debt. The agreement also includes provisions for subsequent payments, dependent on the attainment of regulatory milestones and sales targets. These payments could bring the total value of the transac ...